The tyrosine kinase inhibitor nilotinib targets the discoidin domain receptor DDR2 in calcific aortic valve stenosis,British Journal of Pharmacology

当前位置： X-MOL 学术 › Br. J. Pharmacol. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

The tyrosine kinase inhibitor nilotinib targets the discoidin domain receptor DDR2 in calcific aortic valve stenosis
British Journal of Pharmacology ( IF 6.8 ) Pub Date : 2022-06-25 , DOI: 10.1111/bph.15911
Miguel Carracedo ₁ , Sven-Christian Pawelzik _{1,

2} , Gonzalo Artiach ₁ , Marianne G Pouwer ₃ , Oscar Plunde _{1,

2} , Peter Saliba-Gustafsson ₁ , Ewa Ehrenborg ₁ , Per Eriksson ₁ , Elsbet Pieterman ₃ , Leif Stenke _{1,

4} , Hans M G Princen ₃ , Anders Franco-Cereceda _{2,

5} , Magnus Bäck _{1,

2}

Affiliation

Tyrosine kinase inhibitors (TKI) used to treat chronic myeloid leukaemia (CML) have been associated with cardiovascular side effects, including reports of calcific aortic valve stenosis. The aim of this study was to establish the effects of first and second generation TKIs in aortic valve stenosis and to determine the associated molecular mechanisms.

中文翻译：